BioMarin expands as it tests new drugs

Potential treatments for rare genetic diseases have promise; ‘we need to be ready’

[caption id="attachment_29726" align="alignright" width="360" caption="BioMarin completed a $60 million-plus capital project last year to more than double commercial production capacity at the eight-building campus in the Bel Marin Keys industrial area."][/caption]

NOVATO -- Construction crews have been busy preparing BioMarin Pharmaceutical's facilities in the city for a doubling of production to deliver treatments for testing and sale as well as hiring at least a couple of hundred more employees.

BioMarin completed a $60 million-plus capital project last year to more than double commercial production capacity at the eight-building campus in the Bel Marin Keys industrial area. This year the company continues to expand administrative departments to a ninth building, is upgrading utilities and laboratories and planning further manufacturing growth in 2012, according to Robert Cone, director of capital projects and facilities engineering.

One hundred employees joined the company last year, bringing the total to 700. Roughly another 100 local hires are planned for this year.

"It all depends on the success of our clinical programs," he said. "We need to be ready."


© The North Bay Business Journal  |  Terms of Service |  Privacy Policy |  Jobs With Us |  RSS |  Advertising |  Sonoma Media Investments
Switch to our Mobile View